{"id":70781,"date":"2026-05-12T11:03:24","date_gmt":"2026-05-12T11:03:24","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70781"},"modified":"2026-10-15T10:33:57","modified_gmt":"2026-10-15T10:33:57","slug":"hgh-fragment-176-191","status":"publish","type":"product","link":"https:\/\/medsbase.com\/es\/product\/hgh-fragment-176-191\/","title":{"rendered":"Fragmento HGH 176-191"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Respuesta r\u00e1pida \u2014 \u00bfQu\u00e9 es el fragmento HGH 176-191?<\/h3>\n<p style=\"margin: 0;\"><strong>Fragmento HGH 176-191<\/strong> es un p\u00e9ptido sint\u00e9tico de 16 amino\u00e1cidos correspondiente a los residuos C-terminales 176-191 de <a href=\"https:\/\/medsbase.com\/es\/hgh-191aa\/\">la hormona de crecimiento humana<\/a>. In published studies it retains the lipolytic (fat-mobilising) and glucose-modulating activity of the parent HGH molecule but lacks GH-receptor binding affinity and therefore does not activate IGF-1 production, chondrocyte signalling, or any of the growth-promoting effects of full-length HGH. Sequence: YLRIVQCRSVEGSCGF. Supplied in 5\u201315\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Qu\u00e9 obtienes con MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/es\/reviews\/\">opiniones de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada pedido est\u00e1 cubierto por nuestra <a href=\"https:\/\/medsbase.com\/es\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 si tu paquete no llega en 20 d\u00edas laborables, lo reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especificaci\u00f3n<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalle<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">66004-57-7 (Fragmento HGH 176-191; distinto de AOD9604 CAS 221231-10-9)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>78<\/sub>H<sub>125<\/sub>N<sub>23<\/sub>O<sub>23<\/sub>S<sub>2<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1817.06 Da<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Secuencia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (YLRIVQCRSVEGSCGF, 16 amino\u00e1cidos; posiciones 176\u2013191 de la hormona de crecimiento humana nativa, conservando el puente disulfuro Cys182\u2013Cys189 de la mol\u00e9cula parental)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Polvo liofilizado (blanco a blanquecino)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificado por HPLC, COA bajo solicitud)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Almacenamiento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (refrigerador) para stock de trabajo; \u221220 \u00b0C para almacenamiento a largo plazo de viales sin abrir. Reconstituido: 2\u20138 \u00b0C, usar dentro de ~30 d\u00edas. Proteger de la luz. No congelar-descongelar la soluci\u00f3n reconstituida.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidad<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Agua bacteriost\u00e1tica (recomendada) o agua est\u00e9ril para periodos de uso m\u00e1s cortos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>\u00bfQu\u00e9 es el Fragmento 176-191 de la HGH?<\/h2>\n<p><strong>Fragmento HGH 176-191<\/strong> is a 16-amino-acid synthetic peptide corresponding to the C-terminal residues 176 through 191 of native human growth hormone. The fragment was identified through structure-function studies on HGH conducted at Monash University in the 1990s, when investigators systematically truncated and modified the HGH molecule to map the regions responsible for each of its multiple biological activities. The 176-191 region proved to retain the lipolytic (fat-mobilising) and antilipogenic activity of full-length HGH while completely losing the GH-receptor-binding domain that resides in the N-terminal portion of the parent molecule. The well-characterised sequence is YLRIVQCRSVEGSCGF with the native Cys182\u2013Cys189 intramolecular disulfide bridge preserved (these become Cys7\u2013Cys14 within the fragment numbering). Molecular weight 1817.06\u00a0Da, empirical formula C<sub>78<\/sub>H<sub>125<\/sub>N<sub>23<\/sub>O<sub>23<\/sub>S<sub>2<\/sub>. El Fragmento 176-191 de la HGH es estructural y farmacol\u00f3gicamente <strong>distinto de AOD9604<\/strong> \u2014 an analog developed by Metabolic Pharmaceuticals that adds an N-terminal tyrosine substitution (creating Tyr-HGH 177-191) and modifies the disulfide bridge. AOD9604 has its own CAS (221231-10-9) and pharmacological profile and should not be confused with the unmodified 176-191 fragment supplied here. HGH Fragment 176-191 is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. The fragment is <strong>no est\u00e1 aprobado<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. For the full-length parent molecule, see our <a href=\"https:\/\/medsbase.com\/es\/hgh-191aa\/\">HGH 191AA<\/a> p\u00e1gina de producto. <\/p>\n<h2>Mecanismo de Acci\u00f3n \u2014 Actividad Lipol\u00edtica Sin Uni\u00f3n al Receptor de GH<\/h2>\n<p>Lo que hace que el Fragmento 176-191 de la HGH sea distintivo desde el punto de vista mecan\u00edstico es la <strong>desvinculaci\u00f3n de la lip\u00f3lisis de la se\u00f1alizaci\u00f3n del eje de crecimiento<\/strong> \u2014 one of the cleanest examples of structure-function dissection in peptide pharmacology studies:<\/p>\n<ul>\n<li><strong>Ausencia de uni\u00f3n al receptor de GH<\/strong> \u2014 La superficie de uni\u00f3n al receptor de GH de la HGH nativa se encuentra en la porci\u00f3n N-terminal de la mol\u00e9cula (regi\u00f3n de residuos 1\u2013120), no en el fragmento C-terminal 176\u2013191. Como resultado, el Fragmento 176-191 de HGH NO se une al receptor de la hormona de crecimiento (GHR), NO activa la se\u00f1alizaci\u00f3n JAK2\/STAT5, NO induce la producci\u00f3n hep\u00e1tica de IGF-1 y NO produce ninguno de los efectos promotores del crecimiento, estimulantes de los condrocitos o contrarreguladores de la insulina de la mol\u00e9cula <a href=\"https:\/\/medsbase.com\/es\/hgh-191aa\/\">HGH 191AA<\/a> molecule. This is the defining negative pharmacological property and the basis for its studies utility as a lipolysis-axis-isolating tool.<\/li>\n<li><strong>Actividad lipol\u00edtica preservada<\/strong> \u2014 Published studies has documented that HGH Fragment 176-191 retains the fat-mobilising activity of full HGH at adipocytes. The exact molecular target underlying the lipolytic effect remains an active studies question; proposed mechanisms include direct action on adipocyte beta-3 adrenergic receptors, modulation of hormone-sensitive lipase, and altered fatty-acid oxidation kinetics. The lipolytic signal is preferentially observed in visceral adipose tissue depots in some published rodent studies, paralleling but mechanistically distinct from the <a href=\"https:\/\/medsbase.com\/es\/tesamorelin\/\">Tesamorelin<\/a> visceral-adiposity signal.<\/li>\n<li><strong>Actividad antilipog\u00e9nica<\/strong> \u2014 In addition to stimulating fat mobilisation, HGH Fragment 176-191 suppresses lipogenic gene expression in adipocyte study models \u2014 reducing the rate of new fat storage in parallel with increasing fat mobilisation. The two effects produce a net negative-fat-balance signal in adipose tissue.<\/li>\n<\/ul>\n<p>The structure-function-decoupling property is the principal scientific reason HGH Fragment 176-191 has remained in active studies despite never reaching regulatory approval as a stand-alone therapeutic. It is a useful tool for users who want to study HGH&#8217;s lipolytic effects independently from its growth-promoting effects \u2014 a separation that is impossible to achieve with full-length HGH or with GH secretagogues that drive endogenous full-length GH release. Plasma half-life is short (~30 minutes); subcutaneous administration is the standard administration route. <\/p>\n<h2>Published Evidence<\/h2>\n<p>HGH Fragment 176-191 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Farmacolog\u00eda de la lip\u00f3lisis en adipocitos<\/strong> \u2014 caracterizaci\u00f3n del mecanismo lipol\u00edtico aislado, estudios de interacci\u00f3n con el receptor adren\u00e9rgico beta-3, activaci\u00f3n de la lipasa sensible a hormonas, cin\u00e9tica de movilizaci\u00f3n de \u00e1cidos grasos<\/li>\n<li><strong>Obesity and body-composition studies<\/strong> \u2014 preclinical DIO rodent models, body-composition (DEXA\/MRI), regional adipose-tissue depot effects (visceral vs subcutaneous), lipolysis-without-growth-axis-confound studies designs<\/li>\n<li><strong>HGH structure-function studies<\/strong> \u2014 disecci\u00f3n mecan\u00edstica de los dominios de actividad promotora del crecimiento vs lipol\u00edtica dentro de la HGH nativa; el Fragmento 176-191 de HGH como la herramienta can\u00f3nica \u201csolo lip\u00f3lisis\u201d, con <a href=\"https:\/\/medsbase.com\/es\/hgh-191aa\/\">HGH 191AA<\/a> como el comparador de actividad completa<\/li>\n<li><strong>Lipogenic gene-expression studies<\/strong> \u2014 diferenciaci\u00f3n de adipocitos, formaci\u00f3n de gotas lip\u00eddicas, interacciones de las v\u00edas PPAR\u03b3 y SREBP-1<\/li>\n<li><strong>Visceral adiposity studies<\/strong> \u2014 comparaciones directas con <a href=\"https:\/\/medsbase.com\/es\/tesamorelin\/\">Tesamorelin<\/a> as the GHRH-axis visceral-fat-reducing tool; published interest in dissecting GH-receptor-dependent vs GH-receptor-independent visceral-fat-loss mechanisms<\/li>\n<li><strong>Glucose homeostasis studies<\/strong> \u2014 unlike full-length HGH, HGH Fragment 176-191 does not produce the insulin-counter-regulatory effects observed with parent HGH; published studies uses this difference to dissect direct GH glycaemic effects<\/li>\n<li><strong>Comparative HGH-axis studies<\/strong> \u2014 evaluaci\u00f3n comparativa frente a <a href=\"https:\/\/medsbase.com\/es\/hgh-191aa\/\">HGH 191AA<\/a> (completa original), <a href=\"https:\/\/medsbase.com\/es\/tesamorelin\/\">Tesamorelin<\/a> (an\u00e1logo de GHRH para grasa visceral), y <a href=\"https:\/\/medsbase.com\/es\/sermorelin\/\">Sermorelin<\/a> \/ <a href=\"https:\/\/medsbase.com\/es\/cjc-1295-with-dac\/\">CJC-1295<\/a> (Estimuladores del eje GHRH).<\/li>\n<\/ul>\n<p>For broader context on where HGH Fragment 176-191 fits within the growth-axis and adipose-tissue studies landscape, see <a href=\"https:\/\/medsbase.com\/es\/hgh-191aa\/\">HGH 191AA<\/a> como el p\u00e9ptido parental de longitud completa, <a href=\"https:\/\/medsbase.com\/es\/tesamorelin\/\">Tesamorelin<\/a> para el enfoque del eje GHRH en la adiposidad visceral, y <a href=\"https:\/\/medsbase.com\/es\/sermorelin\/\">Sermorelin<\/a> + <a href=\"https:\/\/medsbase.com\/es\/cjc-1295-with-dac\/\">CJC-1295 con DAC<\/a> for endogenous GH-pulse support. Browse the full <a href=\"https:\/\/medsbase.com\/es\/peptides\/\">cat\u00e1logo de p\u00e9ptidos<\/a> para compuestos relacionados. <\/p>\n<h2>Concentraciones y potencias disponibles<\/h2>\n<p>MedsBase stocks HGH Fragment 176-191 in three lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Potencia del vial<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tama\u00f1os de paquete<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Short protocols, pilot dosing, single-cohort lipolysis studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength, multi-week protocols<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>15 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Protocolos de ciclo extendido, menor costo por mg, estudios de m\u00faltiples cohortes<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All three strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Higher-mg vials require smaller reconstitution volumes per unit dose, which is useful when users want to minimise injection volume in rodent protocols. <\/p>\n<h2>C\u00f3mo se compara \u2014 Fragmento HGH 176-191 vs HGH 191AA<\/h2>\n<p>El Fragmento HGH 176-191 y <a href=\"https:\/\/medsbase.com\/es\/hgh-191aa\/\">HGH 191AA<\/a> are a structure-function decoupled pair \u2014 the fragment is literally a piece of the full-length parent. Comparing them isolates the GH-receptor-binding activity (present in full-length, absent in fragment) from the lipolytic activity (present in both). The comparison is one of the cleanest mechanistic dissections available in current growth-axis studies. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Criterio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Fragmento HGH 176-191<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">HGH 191AA (longitud completa)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Longitud<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">16 amino\u00e1cidos (~1,8 kDa)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">191 amino\u00e1cidos (~22 kDa)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Uni\u00f3n al receptor de GH<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">No (el dominio de uni\u00f3n es N-terminal)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">S\u00ed (mol\u00e9cula de longitud completa)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Inducci\u00f3n de IGF-1<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ninguno<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Inducci\u00f3n hep\u00e1tica sustancial<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Actividad lipol\u00edtica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">S\u00ed (conservada)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">S\u00ed (actividad completa de la mol\u00e9cula parental)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Efectos promotores del crecimiento<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ninguno<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Sustancial (p\u00e9ptido anab\u00f3lico can\u00f3nico)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Efecto contrarregulador de la insulina<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">No<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">S\u00ed (resistencia a la insulina transitoria)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Vida media plasm\u00e1tica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~30 minutos<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~3\u20135 horas<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Uso cl\u00ednico aprobado<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ninguno<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">M\u00faltiples indicaciones (Genotropin, Humatrope, etc.)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dosis t\u00edpica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">200\u2013500\u00a0mcg, 1\u20133 veces al d\u00eda<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">1\u20138\u00a0UI por administraci\u00f3n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies interested in isolated lipolysis pharmacology without the confound of GH-receptor-driven growth and metabolic effects, HGH Fragment 176-191 is the canonical &#8220;lipolysis-only&#8221; tool. For studies investigating the full GH\/IGF axis or comparing with secretagogue-driven endogenous GH release, <a href=\"https:\/\/medsbase.com\/es\/hgh-191aa\/\">HGH 191AA<\/a> is the appropriate full-length reference. Many published studies designs use both in parallel arms to dissect which HGH effects depend on GH-receptor signalling vs which arise from the C-terminal lipolytic mechanism. <\/p>\n<h2>Almacenamiento y reconstituci\u00f3n<\/h2>\n<p><strong>Antes de la reconstituci\u00f3n:<\/strong> almacene los viales liofilizados refrigerados a 2\u20138 \u00b0C en su envase original para existencias de trabajo a corto plazo. Para almacenamiento a largo plazo sin abrir, congele a \u221220 \u00b0C. El fragmento HGH 176-191 liofilizado es estable bajo refrigeraci\u00f3n hasta 24 meses y a \u221220 \u00b0C hasta 36 meses. Evite ciclos de congelaci\u00f3n-descongelaci\u00f3n en el polvo liofilizado. Al igual que otros p\u00e9ptidos con puentes disulfuro, la actividad del fragmento depende del enlace intacto Cys182\u2013Cys189 (numeraci\u00f3n del fragmento Cys7\u2013Cys14) \u2014 cualquier manipulaci\u00f3n que altere el disulfuro degradar\u00e1 la actividad. <strong>Procedimiento de reconstituci\u00f3n:<\/strong> inyecte agua bacteriost\u00e1tica por la pared lateral del vial de p\u00e9ptidos (no directamente sobre el polvo liofilizado). Para un vial de 5 mg, 2.0 mL de agua bacteriost\u00e1tica producen una concentraci\u00f3n de trabajo de 2.5 mg\/mL \u2014 0.04 mL proporcionan 100 mcg; 0.1 mL proporcionan 250 mcg; 0.2 mL proporcionan 500 mcg. Agite suavemente \u2014 no <strong>ajuste<\/strong> shake \u2014 and allow 2\u20135 minutes for full dissolution. A correctly reconstituted solution should be clear and colourless. <strong>Despu\u00e9s de la reconstituci\u00f3n:<\/strong> almacene refrigerado a 2\u20138 \u00b0C y utilice dentro de 30 d\u00edas para una estabilidad \u00f3ptima. No congele la soluci\u00f3n reconstituida \u2014 los ciclos de congelaci\u00f3n-descongelaci\u00f3n degradan la integridad del p\u00e9ptido y pueden alterar el enlace disulfuro. Deseche cualquier vial que presente turbidez, precipitado o decoloraci\u00f3n. <\/p>\n<h2 id=\"faqs\">Preguntas frecuentes<\/h2>\n<h3>What is HGH Fragment 176-191 used for in studies?<\/h3>\n<p>HGH Fragment 176-191 is used in studies investigating isolated adipocyte lipolysis pharmacology, obesity and body-composition regulation without growth-axis confound, HGH structure-function dissection, lipogenic gene-expression regulation, regional adipose-tissue depot effects, and comparative GH-axis vs lipolysis-only studies designs. It is the canonical &#8220;lipolysis-only&#8221; peptide derived from native HGH. The pharmaceutical-grade HGH Fragment 176-191 sold here is <strong>ajuste<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>\u00bfEn qu\u00e9 se diferencia el fragmento HGH 176-191 del HGH 191AA?<\/h3>\n<p>El fragmento HGH 176-191 consta de solo 16 amino\u00e1cidos \u2014 la porci\u00f3n del extremo C-terminal del HGH de longitud completa de 191 amino\u00e1cidos. El fragmento carece del dominio de uni\u00f3n al receptor de GH (que reside en la porci\u00f3n N-terminal de la mol\u00e9cula parental), por lo que NO se une al GHR, NO induce IGF-1 y NO produce ninguno de los efectos promotores del crecimiento o contrarreguladores de la insulina del HGH completo. Solo conserva la actividad lipol\u00edtica y antilipog\u00e9nica. <a href=\"https:\/\/medsbase.com\/es\/hgh-191aa\/\">HGH 191AA<\/a> es la mol\u00e9cula parental de longitud completa con actividad tanto lipol\u00edtica como del eje de crecimiento. <\/p>\n<h3>\u00bfEn qu\u00e9 se diferencia el fragmento HGH 176-191 del AOD9604?<\/h3>\n<p>Son <strong>compuestos distintos<\/strong> that are frequently confused. HGH Fragment 176-191 (CAS 66004-57-7) is the unmodified C-terminal fragment of native HGH. AOD9604 (CAS 221231-10-9) is a modified analog developed by Metabolic Pharmaceuticals \u2014 specifically, AOD9604 adds an N-terminal tyrosine substitution producing Tyr-HGH 177-191, with engineered changes to the disulfide bridge for improved stability and oral bioavailability studies. The two have related but distinct pharmacology. This product is the unmodified 176-191 fragment, not AOD9604. <\/p>\n<h3>What is the typical HGH Fragment 176-191 dose?<\/h3>\n<p>Published preclinical protocols typically use 200\u2013500\u00a0mcg per administration, given subcutaneously 1\u20133 times daily for 4\u201312 week cycles. A 5\u00a0mg vial reconstituted with 2.0\u00a0mL bacteriostatic water yields 2.5\u00a0mg\/mL \u2014 0.04\u00a0mL equals 100\u00a0mcg, 0.2\u00a0mL equals 500\u00a0mcg. <\/p>\n<h3>\u00bfEst\u00e1 aprobado el fragmento HGH 176-191 por la FDA?<\/h3>\n<p>No. HGH Fragment 176-191 is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. The related compound AOD9604 was investigated in clinical trials for obesity but did not achieve regulatory approval. <\/p>\n<h3>\u00bfC\u00f3mo se debe almacenar el fragmento HGH 176-191?<\/h3>\n<p>Viales liofilizados: refrigerados a 2\u20138\u00a0\u00b0C para stock de trabajo a corto plazo, o a \u221220\u00a0\u00b0C para almacenamiento a largo plazo de viales sin abrir. Soluci\u00f3n reconstituida: refrigerada a 2\u20138\u00a0\u00b0C, usar dentro de los 30 d\u00edas. No congelar la soluci\u00f3n reconstituida \u2014 los ciclos de congelaci\u00f3n-descongelaci\u00f3n degradan el p\u00e9ptido y pueden alterar el puente disulfuro esencial Cys182\u2013Cys189. Proteger de la luz directa en todo momento. <\/p>\n<h3>\u00bfC\u00f3mo reconstituyo el fragmento HGH 176-191?<\/h3>\n<p>Siga el procedimiento de reconstituci\u00f3n anterior. A\u00f1ada agua bacteriost\u00e1tica por la pared lateral del vial (no sobre el polvo liofilizado), agite suavemente y permita de 2 a 5 minutos para la disoluci\u00f3n completa. No <strong>ajuste<\/strong> Agite el vial \u2014 la agitaci\u00f3n vigorosa puede alterar el enlace disulfuro. Una soluci\u00f3n correctamente reconstituida es clara e incolora. Para un vial de 5\u00a0mg + 2,0\u00a0mL de diluyente, la concentraci\u00f3n de trabajo es de 2,5\u00a0mg\/mL. <\/p>\n<h3>\u00bfQu\u00e9 concentraciones tiene MedsBase en stock?<\/h3>\n<p>MedsBase carries HGH Fragment 176-191 in 5\u00a0mg, 10\u00a0mg, and 15\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>\u00bfPor qu\u00e9 el fragmento HGH 176-191 no afecta al IGF-1?<\/h3>\n<p>The GH-receptor-binding surface of native human growth hormone is located in the N-terminal portion of the 191-amino-acid molecule, not in the C-terminal 176\u2013191 region. Because the fragment lacks the receptor-binding domain, it cannot activate the GH receptor; without GHR activation, the downstream JAK2\/STAT5 signalling cascade that drives hepatic IGF-1 transcription is not engaged. This structural-functional decoupling is the principal scientific reason the fragment retains studies interest as a lipolysis-isolating tool. <\/p>\n<h3>\u00bfDe d\u00f3nde proviene la actividad lipol\u00edtica si no es de la uni\u00f3n al receptor de GH?<\/h3>\n<p>The exact molecular target of HGH Fragment 176-191&#8217;s lipolytic action remains an active studies question. Proposed mechanisms include direct interaction with adipocyte beta-3 adrenergic receptors, modulation of hormone-sensitive lipase activity, and altered fatty-acid oxidation kinetics in adipose tissue. The fragment also suppresses lipogenic gene expression, suggesting it acts on multiple adipocyte-specific pathways simultaneously. Published studies continues to characterise the exact receptor or binding-site target. <\/p>\n<h3>Does HGH Fragment 176-191 cause side reported effects?<\/h3>\n<p>Published preclinical studies has documented a notably clean safety profile at typical doses, with the main on-target effect being lipolysis. The absence of GH-receptor binding means none of the GH-axis side effects observed with full-length HGH (transient insulin resistance, joint discomfort, sodium retention, mitogenic signalling) are present. Long-term human safety data is limited because the unmodified fragment has not undergone modern regulatory review (though the related AOD9604 has been investigated more extensively in clinical trials). <\/p>\n<h3>\u00bfCu\u00e1l es la vida media del fragmento 176-191 de la HGH?<\/h3>\n<p>In preclinical studies, HGH Fragment 176-191 has a plasma half-life of approximately 30 minutes following subcutaneous administration \u2014 shorter than full-length HGH (~3\u20135 hours) due to the smaller molecular size and absence of albumin-binding modifications. The short half-life means typical protocols use multiple daily administrations or continuous-release formulations for sustained-exposure work. <\/p>\n<h3>How long does HGH Fragment 176-191 take to show effects in preclinical studies?<\/h3>\n<p>Acute effects on adipocyte lipolysis and fatty-acid mobilisation are detectable within hours of administration. Body-composition effects in DIO rodent models typically become statistically significant after 2\u20134 weeks of regular dosing and continue to accrue through 8\u201312 weeks of continuous administration. The kinetics are similar to other adipose-tissue-targeted compounds. <\/p>\n<h3>\u00bfPuedo pedir el fragmento 176-191 de la HGH para env\u00edo internacional?<\/h3>\n<p>S\u00ed. MedsBase env\u00eda el fragmento 176-191 de la HGH a todo el mundo desde nuestra red de env\u00edo dedicada a p\u00e9ptidos. Los pedidos que solo contienen p\u00e9ptidos califican para nuestro servicio de env\u00edo independiente de p\u00e9ptidos. Todos los pedidos se env\u00edan en embalajes con control de temperatura con seguimiento completo y est\u00e1n cubiertos por nuestro <a href=\"https:\/\/medsbase.com\/es\/medsbase-re-shipment-assurance-policy\/\">Reshipment Assurance Policy<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Adipose, Growth-Axis, and Body-Composition Studies<\/h2>\n<ul>\n<li><a href=\"\/es\/hgh-191aa\/\"><strong>HGH 191AA<\/strong><\/a> \u2014 Hormona de crecimiento humana recombinante de longitud completa \u2014 la mol\u00e9cula madre de este fragmento<\/li>\n<li><a href=\"\/es\/tesamorelin\/\"><strong>Tesamorelin<\/strong><\/a> \u2014 GHRH analog \u2014 visceral adipose-tissue studies; FDA-approved for HIV-associated lipodystrophy<\/li>\n<li><a href=\"\/es\/cjc-1295-with-dac\/\"><strong>CJC-1295 con DAC<\/strong><\/a> \u2014 Long-acting GHRH analog \u2014 endogenous GH-pulse support<\/li>\n<li><a href=\"\/es\/sermorelin\/\"><strong>Sermorelin<\/strong><\/a> \u2014 GHRH(1-29) analog \u2014 short-acting GHRH use<\/li>\n<li><a href=\"\/es\/ipamorelin\/\"><strong>Ipamorelina<\/strong><\/a> \u2014 Selective growth hormone secretagogue \u2014 clean GH pulse studies<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Lecturas adicionales<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explore the HGH-axis studies landscape<\/strong><\/p>\n<p style=\"margin: 0;\">Explora toda la <a href=\"https:\/\/medsbase.com\/es\/peptides\/\"><strong>cat\u00e1logo de p\u00e9ptidos<\/strong><\/a>, con compuestos relacionados del eje del crecimiento que incluyen <a href=\"https:\/\/medsbase.com\/es\/hgh-191aa\/\">HGH 191AA<\/a> (completa original), <a href=\"https:\/\/medsbase.com\/es\/tesamorelin\/\">Tesamorelin<\/a> (an\u00e1logo de GHRH para adiposidad visceral), <a href=\"https:\/\/medsbase.com\/es\/sermorelin\/\">Sermorelin<\/a> y <a href=\"https:\/\/medsbase.com\/es\/cjc-1295-with-dac\/\">CJC-1295 con DAC<\/a> for endogenous-pulse studies.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Fragmento C-terminal de 16 aa de la hormona de crecimiento humana<br \/>\n\u2705 Conserva la actividad lipol\u00edtica, sin uni\u00f3n al receptor de GH<br \/>\n\u2705 Sin inducci\u00f3n de IGF-1 ni efectos promotores del crecimiento<br \/>\n\u2705 Lipolysis-only tool (distinct from AOD9604)<br \/>\n\u2705 Pureza \u226599% por HPLC, COA disponible bajo solicitud<\/p>\n<p><strong>Fragmento HGH 176-191<\/strong> contiene compuesto de p\u00e9ptido sint\u00e9tico.<\/p>","protected":false},"featured_media":70959,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6288,6289,5441],"class_list":["post-70781","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-hgh","product_tag-hgh-fragment","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product\/70781","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/comments?post=70781"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media\/70959"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media?parent=70781"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_brand?post=70781"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_cat?post=70781"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_tag?post=70781"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}